Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Raymond James issued their Q4 2024 earnings per share estimates for shares of Knight Therapeutics in a research report issued on Wednesday, November 13th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics' Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.
Several other brokerages also recently weighed in on GUD. Stifel Nicolaus raised shares of Knight Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 12th.
Check Out Our Latest Research Report on GUD
Knight Therapeutics Price Performance
Shares of GUD traded down C$0.03 during mid-day trading on Friday, reaching C$5.19. The stock had a trading volume of 103,432 shares, compared to its average volume of 69,560. The business has a fifty day moving average of C$5.71 and a 200 day moving average of C$5.73. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The firm has a market cap of C$525.28 million, a price-to-earnings ratio of -25.95, a PEG ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 12 month low of C$5.07 and a 12 month high of C$6.23.
Insider Activity at Knight Therapeutics
In other news, Director Samira Sakhia bought 20,000 shares of Knight Therapeutics stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00. 45.62% of the stock is currently owned by corporate insiders.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
